{'fraction_non_alphanumeric': 0.01300578034682081, 'fraction_numerical': 0.014450867052023121, 'mean_word_length': 5.1875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hormonal Therapy Trials in Prostatic Cancer An EORTC Genitourinary Group Study

In this paper the authors review the completed and current EORTC Genitourinary Group trials for metastatic carcinoma of the prostate. In terms of time to progression and length of survival, there is no significant difference between any of the effective endocrine treatments that have been studied. The statistical analysis of the different variables used in trials 30.761 and 30.762 determines three risk groups of patients. There is no need for very special laboratory investigations to establish a prognosis. Or-chiectomy is the cheapest and safest endocrine treatment in metastatic carcinoma of the prostate.